Tosedostat (CHR2797)

Tosedostat (CHR2797) is an aminopeptidase inhibitor for LAP, PuSA and Aminopeptidase N with IC50 of 100 nM, 150 nM and 220 nM, respectively, and does not effectively inhibit either PILSAP, MetAP-2, LTA4 hydrolase, or MetAP-2. Phase 2.

Tosedostat (CHR2797)化学構造

CAS No. 238750-77-1

サイズ 価格(税別) 在庫状況
JPY 29300 国内在庫あり
JPY 76500 国内在庫あり

代表番号: 045-509-1970|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(3)

製品安全説明書

現在のバッチを見る: 純度: 99.98%
99.98

Tosedostat (CHR2797)関連製品

Aminopeptidase阻害剤の選択性比較

生物活性

製品説明 Tosedostat (CHR2797) is an aminopeptidase inhibitor for LAP, PuSA and Aminopeptidase N with IC50 of 100 nM, 150 nM and 220 nM, respectively, and does not effectively inhibit either PILSAP, MetAP-2, LTA4 hydrolase, or MetAP-2. Phase 2.
Targets
LAP [1] PuSA [1] Aminopeptidase N [1]
100 nM 150 nM 220 nM
In Vitro
In vitro CHR-2797 has almost no effect on Aminopeptidase B, PILSAP, LTA4 hydrolase and MetAP-2 activity with IC50 values of >1 uM, >5 uM, >10 uM and >30 uM, respectively. CHR-2797 is converted into a pharmacologically active acid product (CHR-79888) inside cells, which shows significant inhibitory activity towards LTA4 hydrolase with IC50 of 8 nM. CHR-2797 exhibits profound anti-proliferative effects against a range of cancer cell lines such as U-937, HL-60, KG-1 and GDM-1 with IC50 values of 10 nM, 30 nM, 15 nM and 15 nM, respectively, but is inactive against HuT 78 and Jurkat E6-1 with IC50 values of >10 uM. There is no obvious correlation between sensitivity to CHR-2797 and the mutational status of p53, PTEN, or K-Ras in cells. CHR-2797 shows selectivity for transformed cells (MrC5-SV2 or K-ras NRK) over non-transformed cells (MrC5 or NRK). CHR-2797 (6 μM) treatment leads to the up-regulation of genes involved in amino acid transport and metabolic pathways, the phosphorylation of eukaryotic initiation factor 2α, the inhibition of phosphorylation of mTOR substrates and reduced protein synthesis in HL-60 cells. [1]
Kinase Assay Aminopeptidase assays
LAP activity is determined by measuring the hydrolysis of the tripeptide, LGG, which is detected by the derivatization reagent OPA in the presence of β-mercaptoethanol. The assay is carried out in 96-well assay plates. Wells contain diluted CHR-2797 (5 μL), 10 μg/mL LAP (5 μL) and 40 μL of 0.5 mM LGG. The plate is shaken briefly, and incubated for 90 minutes at 37 °C. The reaction is terminated by addition of 200 μL of OPA/β-Mercaptoethanol per well. The plate is read on the Victor Wallac3 plate reader: excitation, 355nm and emission, 460nm. PuSA activity is determined using the fluorogenic substrate Ala-AMC. Incubation mix contains diluted CHR-2797 (20 μL), substrate (125 μM Ala-AMC in 0.125 M Tris-HCl buffer, pH 7.5; 40 μL) and enzyme (40 μL). After incubation for 2 hours at 37 °C, the reaction is stopped by addition of 100 μL 3% (v/v) acetic acid. Fluorescence is measured using a SLT Fluostar fluorimeter. Aminopeptidase N is assayed using the fluorogenic substrate, Ala-AMC. Incubation mix contains diluted CHR-2797 (20 μL), substrate (40 μL; final concentration, 60 μM) and enzyme (40 μL, 1:8000 dilution) and is incubated for 60 minutes at 37 °C prior to addition of 100 μL 3% (v/v) acetic acid, to stop the reaction. Fluorescence is measured using a SLT Fluostar fluorimeter.
細胞実験 細胞株 U-937, HL-60, KG-1, HNT-34 and GDM-1
濃度 Dissolved in DMSO, final concentration ~1 mM
反応時間 72 hours
実験の流れ Cells are exposed to different concentrations of CHR-2797 for 72 hours. During the final 4 hours of this incubation, cells are pulsed with 0.4 μCi/well of [3H]thymidine (specific activity, 5 mCi/mmol), harvested onto GF/C glass fiber filter mats using a Tomtec harvester, and counted on a 1450 MicroBeta scintillation counter to determine the amount of [3H]thymidine incorporated into cellular DNA. Inhibition of the proliferation of human cancer cell lines is measured by [3H]thymidine incorporation.
In Vivo
In Vivo Administration of CHR-2797 (~100 mg/kg) decreases tumor volumes in vivo, compared to controls, in a dose-response manner in the rat HOSP.1 lung colonisation model, the rat HSN LV10 chondrosarcoma liver colonisation model, the human MDA-MB-435 breast cancer spontaneous metastasis model, and the human MDA-MB-468 cell xenograft model. [1]
動物実験 動物モデル Female rats (CBH/cbi) injected i.v. with HOSP.1P cells, male (CBH/cbi) rats injected with HSN LV10 cells, and nude mice (MF1 (nu/nu) inoculated with MDA-MB 435 cells or MDA-MB-468 cells
投与量 ~100 mg/kg
投与経路 Dosed daily p.o.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01180426 Unknown status
Acute Myeloid Leukemia
Chroma Therapeutics
June 2010 Phase 2
NCT00780598 Completed
Acute Myeloid Leukemia|AML
Chroma Therapeutics|Quintiles Inc.
October 2009 Phase 2
NCT00522938 Terminated
Carcinoma Non-Small-Cell Lung
Chroma Therapeutics
December 2007 Phase 1|Phase 2
NCT00737555 Completed
Solid Tumor
Chroma Therapeutics
August 2006 Phase 1
NCT00689000 Completed
Acute Myeloid Leukemia|Myelodysplastic Syndrome|Multiple Myeloma
Chroma Therapeutics
May 2006 Phase 1|Phase 2

化学情報

分子量 406.47 化学式

C21H30N2O6

CAS No. 238750-77-1 SDF Download Tosedostat (CHR2797) SDFをダウンロードする
Smiles CC(C)CC(C(C(=O)NO)O)C(=O)NC(C1=CC=CC=C1)C(=O)OC2CCCC2
保管

In vitro
Batch:

DMSO : 56 mg/mL ( (137.77 mM); 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Ethanol : 14 mg/mL

Water : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください
Tags: Tosedostat (CHR2797)を買う | Tosedostat (CHR2797) ic50 | Tosedostat (CHR2797)供給者 | Tosedostat (CHR2797)を購入する | Tosedostat (CHR2797)費用 | Tosedostat (CHR2797)生産者 | オーダーTosedostat (CHR2797) | Tosedostat (CHR2797)化学構造 | Tosedostat (CHR2797)分子量 | Tosedostat (CHR2797)代理店